Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company provides pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

Abbott Laboratories

Insiders have been trading these 5 stocks: (($ABT)), (($VST)), (($U)), (($UAL)) and (($NU)). Here is a breakdown of their recent trades and their v...

Abbott, Vistra, Unity, United, Nu: Insider Shockwave

Shares in medical technology group Boston Scientific ($BSX) dipped over 3% in pre-market trading after it revealed it had been hit by a major cyber...

Boston Scientific Stock (BSX) Plunges After Global Cybersecurity Incident

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Savara (SVRA), AptarGroup (ATR) and Abbott Laborator...

Analysts Offer Insights on Healthcare Companies: Savara (SVRA), AptarGroup (ATR) and Abbott Laboratories (ABT)

In a report released yesterday, Larry Biegelsen from Wells Fargo maintained a Buy rating on Abbott Laboratories, with a price target of $112.00. Th...

Wells Fargo Keeps Their Buy Rating on Abbott Laboratories (ABT)

Abbott Laboratories ( ($ABT) ) just unveiled an update. On August 20, 2026, Abbott announced agreements with three law firms to settle the Gill cas...

Abbott settles major preterm formula litigation claims

Insiders have been trading these 5 stocks: (($ENPH)), (($OPEN)), (($ABT)), (($TTWO)) and (($NDAQ)). Here is a breakdown of their recent trades and ...

Enphase, Opendoor, Abbott, Take-Two, Nasdaq Insider Shocks

A federal judge in Illinois has dismissed the amended complaint in an investor lawsuit against Abbott Laboratories (ABT) over statements tied to th...

Court Dismisses Amended Securities Complaint Against Abbott Laboratories 

In a report released today, Joanne Wuensch from Citi maintained a Buy rating on Abbott Laboratories, with a price target of $125.00. According to T...

Abbott Laboratories (ABT) Receives a Buy from Citi

Abbott Laboratories ($ABT) announced an update on their ongoing clinical study. The PULSE Study is a new trial looking at early treatment for atria...

Early AF Treatment on Trial: What Abbott’s PULSE Study Could Mean for Investors

Abitare In SpA ( ($IT:ABT) ) has shared an update. Abitare In S.p.A. has made available the minutes of its shareholders’ meeting held on July 20, 2...

Abitare In Publishes Minutes of July 20 Shareholders’ Meeting

Abits Group ( ($ABTS) ) just unveiled an update. On August 6, 2026, Abits Group CEO Conglin Deng transferred all of his beneficial interests in the...

Abits Group Hands 47% Voting Control to ARC, Reshapes Board and Governance in August 2026

In a report released today, Travis Steed from Bank of America Securities maintained a Buy rating on Abbott Laboratories, with a price target of $11...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ABT	$108.33	-0.42%	7.03M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ABT	$108.33	-0.4%	7.03M
3
4
5
6

ABT

Get Abbott Laboratories Data in Excel

Get Abbott Laboratories Data in Excel